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divergences, such as polymorphisms in
the primer-binding regions, our present
study might underestimate the frequen-
cies detectable in the skin cancer
samples. Nevertheless, the copy number
of the viruses per human genome within
the positive tested samples was very
low. In the representative examples
depicted in Figure 1c, HPyV6 showed
much higher cycle thresholds than the
cellular gene control thyroid peroxidase,
which is normally unaffected by gains
and losses in MCC and thus should
represent a curve for two copies per cell
(Paulson et al., 2009). The more fre-
quent presence of HPyV6 compared
with HPyV7 among the skin tumor
samples is in line with the serological
data available for these viruses (Scho-
walter et al., 2010). The observations of
a similar detection rate of HPyV6 and
HPyV7 on the skin surface of healthy
volunteers, the higher seropositivity for
HPyV6, and an increased presence of
HPyV6 in skin tumor samples are
suggestive for either a broader cell
tropism, a higher survival capability
within the skin, or a more efficient skin
entry mechanism of HPyV6. The low
viral load presence of HPyV6 and
HPyV7 in some of the cancer samples
reflects the situation of MCV, which can
also be detected at low quantities in
different tissue specimens irrespective of
the pathological status (Loyo et al.,
2010). In summary, the low level pre-
sence of HPyV6 and HPyV7 within the
108 analyzed skin cancer samples, i.e.,
clearly lower than one viral copy per
cell, does not deliver any evidence for a
significant role of these polyomaviruses
for the pathology of the respective skin
cancers, but it certainly exclude a role of
these viruses in the maintenance of the
malignant phenotype of the analyzed
skin cancers.
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TO THE EDITOR
Epidermal Langerhans cells (LCs) are
central in various aspects of skin
biology, but the fact that the cells are
the sole cell type constitutively express-
ing high levels of CD1a molecules has
been appreciated only when research-
ers use CD1a as a specific marker of
human LCs. Although we (Sugita et al.,
1999; Pena-Cruz et al., 2003) and
others (Hunger et al., 2004; de Jong
et al., 2010) recently reported studies
focusing on the functional role of CD1a
in lipid antigen presentation and T-cell
activation in the skin, a fundamental
question remains to be addressed as to
how such high levels of CD1a expression
are maintained in LCs. Certain factors
and stimuli have been implicated in
CD1a expression in myelomonocytic
cells, among which GM-CSF is the most
important because of its ability to induce
CD1a transcription and translation, as
well as differentiation into LC-like cells
www.jidonline.org 241
C Kobayashi et al.
GM-CSF-Independent CD1a Expression in Epidermal LCs
in combination with other bioactive
factors (Caux et al., 1992; Geissmann
et al., 1998; Mohamadzadeh et al.,
2001). Given that keratinocytes, the
major symbionts of LCs, are a potential
source of GM-CSF, it can be reasonably
hypothesized that the constitutive CD1a
expression in LCs may be induced and
sustained by GM-CSF present in the
epidermal microenvironment; however,
it is not an easy task to test this, as mice
and rats, for which gene manipulation
protocols are readily available, have
deleted the CD1A gene and thus LCs
in these animals lack the expression of
CD1a molecules. Alternatively, we took
advantage of this genetic defect and
established a murine transgenic (Tg) line
carrying a cloned fragment of the human
genomic CD1A gene (Figure 1a). We
then mated the human CD1a Tg mice
with GM-CSF knockout mice (Dranoff
et al., 1994), hoping to directly address
the hypothesis raised above.
It is an essential requirement for this
study that the cellular distribution of
CD1a molecules in humans should be
reconstituted faithfully in CD1a Tg
mice. We confirmed that LCs
(Figure 1b–d) and immature thymocytes
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Figure 1. CD1a expression in Langerhans cells of the CD1a Tg mice. (a) Schematic view of the cloned human CD1A genome (5,833 bp) used for the generation
of transgenic (Tg) mice. Black boxes indicate exons (E). Filled and unfilled arrowheads indicate the position of the sense and antisense primers, respectively,
designed for PCR-based genotyping. (b) The epidermal sheet obtained from the ear auricle of the CD1a Tg mouse was fixed, permeabilized, and labeled with the
10H3 mouse mAb to human CD1a molecules and FITC-conjugated donkey antibodies to mouse IgG. Note that the reticular network of CD1a-positive dendritic
cells is visualized. Bar¼ 20mm. (c) An ultrathin cryosection (100 nm) of the ear skin obtained from the CD1a Tg mouse was generated, followed by labeling with
the 10H3 anti-CD1a antibody and Alexa Fluor 488-conjugated goat polyclonal antibodies to mouse IgG. Nuclei were stained with 4’,6-diamidino-2-
phenylindole. The border of the epidermis is indicated with white lines. Note the presence of a CD1a-positive dendritic cell with a convoluted nucleus
in the suprabasal layer of the epidermis. Bar¼5 mm. (d) The epidermal cell suspension of the CD1a Tg mouse was double labeled with FITC-conjugated
antibodies to CD1a and R-Phycoerythrin-conjugated antibodies to langerin, and analyzed by flow cytometry. Note that langerin-positive Langerhans cells
(LCs) express CD1a molecules. (e) The CD4/CD8 double-negative (DN), double-positive (DP), CD4 single-positive (SP), and CD8 SP thymocytes derived from
the CD1a Tg mouse were analyzed for CD1a expression by three-color flow cytometry. Note that DP immature thymocytes prominently express CD1a
molecules. (f) Bone marrow-derived macrophages isolated from the CD1a Tg mouse were stimulated in vitro with recombinant GM-CSF. The cells were then
collected at the indicated time points, and RNA was extracted, followed by RT-PCR for detection of CD1A and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcripts. (g) GM-CSF-stimulated (right panel) and mock-stimulated (left panel) bone marrow macrophages from the CD1a Tg mouse were labeled
with FITC-conjugated antibodies to CD1a and analyzed by flow cytometry.
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(Figure 1e) in these mice specifically
and almost exclusively expressed the
transgene. Furthermore, macrophages
derived from the bone marrow of
CD1a Tg mice were induced to tran-
scribe the human CD1A transgene
upon in vitro stimulation with recombi-
nant GM-CSF (Figure 1f) and expressed
the gene product on the cell surface
(Figure 1g). These observations re-
vealed a trans-species gene activation
pathway in which murine transcription
factors that would be required for
transcription of the human CD1A gen-
ome functioned properly, resulting in
the constitutive and GM-CSF-induced
expression of CD1a molecules.
We then analyzed the CD1a expres-
sion on LCs either in the presence or
absence of endogenous GM-CSF. CD1a
Tg mice carrying heterozygous (þ /)
or homozygous (/) mutations in the
GM-CSF genes were identified by the
genomic PCR (Figure 2a), and LCs were
isolated from the epidermis, followed
by flow cytometric analysis for CD1a
expression. Representative histograms
are shown in Figure 2b, indicating that
the profiles are comparable between
the two groups. Analysis of six animals
in each group revealed that the level of
CD1a expression on LCs, determined
by the mean fluorescence intensity, was
unaffected in the absence of endogen-
ous GM-CSF (Figure 2c).
The present study demonstrates that
the 1,421 bp upstream sequence of the
CD1A genome is sufficient for its highly
cell-type-specific expression. Further-
more, the short stretch of the genome
is sufficient for GM-CSF-induced ex-
pression of CD1a molecules in vitro,
but their steady-state expression in LCs
is regulated independently of this cyto-
kine. This is consistent with the notion
that GM-CSF may function critically for
emergency myelopoiesis, which is large-
ly dispensable for steady-state hema-
topoiesis and for murine dendritic cell
differentiation (Dranoff et al., 1994;
Metcalf, 2008). Alternatively, signals
through receptors for IL-3 and IL-5,
which share the signaling b-chain with
the GM-CSF receptor, may contribute
to CD1a expression in LCs, and it will
now be possible to dissect the role of
these pathways by using the CD1a Tg
mice. The identification of LC-specific,
but GM-CSF-independent, cellular
signals and pathways directed
toward the short stretch of the CD1A
genome would eventually provide im-
portant implications in LC and CD1a
biology.
All animal experiments were con-
ducted according to the institutional
guidelines on animal welfare and the
humane treatment of laboratory animals.
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Figure 2. GM-CSF-independent expression of CD1a molecules by LCs. (a) PCR-based genotyping patterns are shown for the wild-type mouse (wt, þ /þ ),
CD1a transgenic (Tg) mouse carrying wild-type GM-CSF genes (CD1a Tg, þ /þ ), and CD1a Tg mice carrying either heterozygous (CD1a Tg, þ /) or
homozygous (CD1a Tg, /) mutations in GM-CSF genes. (b, c) Epidermal cell suspensions obtained from the CD1a Tg mice carrying heterozygous
(left panel in b) or homozygous (right panel in b) mutations in GM-CSF genes were labeled with R-Phycoerythrin-conjugated antibodies to CD1a and
analyzed by flow cytometry. The mean fluorescence intensity (MFI) values and the standard deviations obtained after analysis of six animals in each group
are shown in c.
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SLIT Prevents the Development of Eczema in
Percutaneous Allergen-Sensitized Mice
Journal of Investigative Dermatology (2012) 132, 244–246; doi:10.1038/jid.2011.278; published online 8 September 2011
TO THE EDITOR
Atopic dermatitis (AD) is a T-cell-
mediated chronic inflammatory skin
disease associated with cutaneous hy-
perreactivity to environmental antigens,
such as house dust mite Dermatopha-
goides farinae (DF), which are innoc-
uous to normal nonatopic individuals
(Bieber, 2008). The hallmarks of AD are
skin barrier dysfunction and T-cell
infiltration, which are intimately linked.
Current approaches to treating AD are
directed at both the restoration of
barrier function and the inhibition of
inflammation. Development of new
targeted therapeutic approaches is a
constant preoccupation. Sublingual im-
munotherapy (SLIT) is an efficacious
treatment for type I (IgE-mediated)
respiratory allergies (Canonica and
Passalacqua, 2006; Didier et al., 2007)
aimed at inducing allergen-specific
tolerance. Until now, SLIT is not
indicated for AD, and few data are
available for either animal models or
humans (Pajno et al., 2007). Here, we
tested the efficacy of SLIT against house
dust mite DF in a mouse model of AD,
as a proof of concept of using allergen-
specific immunotherapy in type IV
(T-cell-mediated) skin allergy. In this
DF-induced AD model, we have pre-
viously shown that CD8þ T cells
producing IFN-g are essential for the
development of AD skin inflammation
(Hennino et al., 2007). The importance
of CD8þ T cells has been previously
described in the physiopathology of the
human disease (Akdis et al., 1999;
Seneviratne et al., 2002; Hennino
et al., 2011). Upon DF skin sensitiza-
tion, CD8þ T cells are induced in
draining lymph nodes and recruited
in the challenged skin where they
initiate the AD-like skin inflammatory
reaction.
Mice were sensitized on the ear
once a week for 4 weeks by application
of a solution of DF (250 mg per applica-
tion), as previously described (Hennino
et al., 2007). Mice developed a specific
ear inflammation 24–48 hours after the
fourth DF skin challenge (day 21), but
also at distant challenge times per-
formed 4 (day 49) or 8 weeks (day 91)
later (Supplementary Figure S1A, B on-
line). Sensitized animals displayed an
average frequency of IFN-g spot-form-
ing cells (SFC) of 45 cells per 106 spleen
cells (data not shown), as detected by
the ELISPOT technique. SLIT treatment
was performed on unanesthetized mice
using chitosan-formulated DF (CHI-DF)
or the placebo control CHI-empty
particules (CHI-F) twice a week for 8
consecutive weeks (from D28 to D88)
in previously sensitized animals
(D0–D21; Figure 1a). Concentration of
DF in the particulated CHI was 8.3
times less than the immunization dose
(i.e., 30 mgml1). CHI, a polysaccha-
ride derived from chitin by deacetyla-
tion, had been previously identified to
enhance allergen-specific tolerance
when co-administrated sublingually
with the antigen in ovalbumin-sensi-
tized asthmatic mice (Razafindratsita
et al., 2007; Saint-Lu et al., 2009). As
shown in Figure 1b, mice treated with
CHI-DF did not develop DF-induced
skin inflammation 48 hours upon chal-
lenge, in contrast to placebo CHI-
F-treated mice, suggesting that SLIT
induced allergen-specific tolerance.
An important finding was also that
CHI-DF treatment of unsensitized mice
did not lead to ear inflammation upon
challenge, demonstrating that repeated
sublingual allergen exposure does not
induce sensitization. Next, we analyzed
the immune response in the spleen of
CHI-DF- or CHI-F-treated mice. Mice
were killed at day 91 and spleens were
recovered and restimulated in vitro
with DF antigen for 48 hours, and the
frequency of IFN-g-producing cells was
evaluated by ELISPOT assay. Spleen
cells were dispensed in the plates
(5105 per well) and incubated with
500mgml1 Der f protein or Der f
peptide at 2mM (data not shown) for
36 hours at 37 1C, 5% CO2 in the
presence of irradiated splenocytes as
antigen-presenting cells. To determine
Der f, class I peptide was also used for
Abbreviations: AD, atopic dermatitis; CHI, chitosan; DF, Dermatophagoides farinae; SFC, spot-forming
cells; SLIT, sublingual immunotherapy
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